Andere Sprachen Lexaria Bioscience Corp.

Aktien

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:01 03.05.2024			% 5 Tage	% 1. Jan.
3,13 ^USD	+4,33 %		+33,19 %	+150,40 %

16.04.	Lexaria Bioscience Corp. erhält Genehmigung der Ethikkommission für den Beginn einer neuen GLP-1-Studie	CI
09.04.	Lexaria Bioscience Corp. meldet Ergebnis für das zweite Quartal und die sechs Monate bis zum 29. Februar 2024	CI

Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuance	30.04.
Lexaria Obtains Ethics Review Board Approval to Start New GLP-1 Study	16.04.
Lexaria Bioscience Corp. Receives Ethics Review Board Approval to Begin New GLP-1 Study	16.04.
Lexaria Bioscience : Corporate Highlight Sheet	11.04.
Lexaria Bioscience Corp. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	09.04.
Lexaria Bioscience Corp. Receives New Patents in the Fields of Epilepsy and Anti-Viral Agents	02.04.
Lexaria Awarded New Patents	02.04.
Lexaria Bioscience : Amendment of a Material Definitive Agreement - Form 8-K	21.03.
Lexaria to Present at The LD Micro Invitational XIV	21.03.
Lexaria Bioscience Names Nelson Cabatuan as Finance Chief	14.03.
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer	14.03.
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer	14.03.
Lexaria Bioscience : Corporate Highlight Sheet	08.03.
Lexaria Awards Contract For Next GLP-1 Human Pilot Study	07.03.
Sector Update: Health Care Stocks Retreating Late Afternoon	05.03.
Sector Update: Health Care	05.03.
Lexaria Bioscience to Start Diabetes, Weight Loss Animal Study; Shares Rise	05.03.
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1	05.03.
Lexaria to Begin Diabetes and Weight Loss Animal Study Well-A24-1	05.03.
Lexaria Bioscience Corp. Signs Contracts to Begin Animal Study Well-A24-1	04.03.

Keine Ergebnisse zu dieser Suche